Kodiak

$87.87 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Kodiak

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.

Stock Analysis

last close $87.87
1-mo return -3.3%
3-mo return -28.4%
avg daily vol. 256.09T
52-week high 171.21
52-week low 45.02
market cap. $4.4B
forward pe -
annual div. -
roe -27.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 89.5%
baraka

Subscribe now for daily local and international financial news

Subscribe